{"nctId":"NCT00300456","briefTitle":"Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood","startDateStruct":{"date":"2006-03"},"conditions":["Dyslipidemia","Coronary Heart Disease","Mixed Dyslipidemia"],"count":657,"armGroups":[{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Simvastatin"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Simvastatin"]},{"label":"C","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Placebo"]},{"label":"D","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Simvastatin","Drug: Placebo"]},{"label":"E","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Simvastatin","Drug: Placebo"]},{"label":"F","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Simvastatin","Drug: Placebo"]}],"interventions":[{"name":"ABT-335","otherNames":[]},{"name":"Simvastatin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with mixed dyslipidemia\n* Subjects agree to utilize adequate birth control methods and to adhere to the American Heart Association (AHA) diet.\n\nExclusion Criteria:\n\n* Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.\n* Patients who are taking certain medications or unstable dose of specific medications.\n* Women who are pregnant or plan on becoming pregnant, or women who are lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change in Triglycerides From Baseline to Final Visit","description":"\\[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.4","spread":"2.75"},{"groupId":"OG001","value":"-42.7","spread":"2.77"},{"groupId":"OG002","value":"-31.7","spread":"2.74"},{"groupId":"OG003","value":"-14.2","spread":"2.71"},{"groupId":"OG004","value":"-22.4","spread":"2.76"},{"groupId":"OG005","value":"-20.2","spread":"3.82"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit","description":"\\[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"1.86"},{"groupId":"OG001","value":"18.9","spread":"1.86"},{"groupId":"OG002","value":"16.2","spread":"1.85"},{"groupId":"OG003","value":"7.2","spread":"1.80"},{"groupId":"OG004","value":"8.5","spread":"1.89"},{"groupId":"OG005","value":"6.8","spread":"2.61"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit","description":"\\[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.0","spread":"1.94"},{"groupId":"OG001","value":"-25.3","spread":"1.96"},{"groupId":"OG002","value":"-4.0","spread":"1.96"},{"groupId":"OG003","value":"-22.4","spread":"1.90"},{"groupId":"OG004","value":"-31.7","spread":"1.98"},{"groupId":"OG005","value":"-40.8","spread":"2.69"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit","description":"\\[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.7","spread":"1.48"},{"groupId":"OG001","value":"-35.0","spread":"1.48"},{"groupId":"OG002","value":"-17.3","spread":"1.46"},{"groupId":"OG003","value":"-24.4","spread":"1.43"},{"groupId":"OG004","value":"-35.9","spread":"1.49"},{"groupId":"OG005","value":"-40.6","spread":"2.06"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C)From Baseline to Final Visit","description":"\\[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.9","spread":"4.06"},{"groupId":"OG001","value":"-51.1","spread":"4.03"},{"groupId":"OG002","value":"-36.9","spread":"4.04"},{"groupId":"OG003","value":"-19.2","spread":"4.04"},{"groupId":"OG004","value":"-35.7","spread":"4.06"},{"groupId":"OG005","value":"-30.0","spread":"5.66"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Total Cholesterol From Baseline to Final Visit","description":"\\[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":"1.20"},{"groupId":"OG001","value":"-27.1","spread":"1.21"},{"groupId":"OG002","value":"-12.4","spread":"1.20"},{"groupId":"OG003","value":"-19.8","spread":"1.19"},{"groupId":"OG004","value":"-30.0","spread":"1.21"},{"groupId":"OG005","value":"-33.6","spread":"1.67"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit","description":"\\[(Week 12 Apo B minus baseline Apo B)/baseline Apo B\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.5","spread":"1.47"},{"groupId":"OG001","value":"-31.2","spread":"1.47"},{"groupId":"OG002","value":"-17.6","spread":"1.45"},{"groupId":"OG003","value":"-22.9","spread":"1.45"},{"groupId":"OG004","value":"-32.7","spread":"1.46"},{"groupId":"OG005","value":"-38.9","spread":"2.05"}]}]}]},{"type":"SECONDARY","title":"Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Final Visit","description":"\\[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.8","spread":"48.27"},{"groupId":"OG001","value":"-32.1","spread":"48.70"},{"groupId":"OG002","value":"-15.8","spread":"48.01"},{"groupId":"OG003","value":"-11.4","spread":"48.18"},{"groupId":"OG004","value":"-14.8","spread":"48.25"},{"groupId":"OG005","value":"-19.8","spread":"67.84"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Headache","Back pain","Nasopharyngitis","Upper respiratory tract infection","Arthralgia"]}}}